EUVIMEDEUVIMED entdecken
Crossref

Proprotein Convertase Subtilisin/Kexin type 9: una storia tutta traslazionale

Francesco Baratta, Vittoria Cammisotto, Arianna Pani, Laura D’Erasmo

Il Diabete · 07.05.2026 · 38 (1)

DOI: 10.30682/ildia2601f ↗

Kurz gefasst

Fachartikel in der Zeitschrift Il Diabete, online erschienen am 07.05.2026. Verfasst von Francesco Baratta und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PCSK9 inhibitors have marked a major advance in the treatment of dyslipidemia and cardiovascular prevention, representing a paradigmatic example of translational research “from gene to drug”. From the discovery of PCSK9 and its role in LDL receptor degradation to the development of monoclonal antibodies and siRNA-based therapies such as inclisiran, progress has been linear and biologically driven. Beyond LDL lowering and cardiovascular risk reduction, ancillary effects on platelet function and glucose metabolism have been investigated. Although PCSK9 loss-of-function variants are associated with a modest increase in diabetes risk, experimental and clinical evidence shows that inhibition of circulating or hepatic PCSK9 does not impair pancreatic β-cell function, supporting its metabolic safety.

Zitieren

APA

Baratta, F., Cammisotto, V., Pani, A., & D’Erasmo, L. (2026). Proprotein Convertase Subtilisin/Kexin type 9: una storia tutta traslazionale. Il Diabete, 38(1). https://doi.org/10.30682/ildia2601f

Vancouver

Baratta F, Cammisotto V, Pani A, D’Erasmo L. Proprotein Convertase Subtilisin/Kexin type 9: una storia tutta traslazionale. Il Diabete. 2026;38(1). doi:10.30682/ildia2601f

BibTeX
@article{Baratta2026,
  author = {Baratta, Francesco and Cammisotto, Vittoria and Pani, Arianna and D’Erasmo, Laura},
  title = {Proprotein Convertase Subtilisin/Kexin type 9: una storia tutta traslazionale},
  journal = {Il Diabete},
  year = {2026},
  volume = {38},
  number = {1},
  doi = {10.30682/ildia2601f}
}
Kostenlos starten →